AR040090A1 - Nueva combinacion - Google Patents

Nueva combinacion

Info

Publication number
AR040090A1
AR040090A1 ARP030101762A ARP030101762A AR040090A1 AR 040090 A1 AR040090 A1 AR 040090A1 AR P030101762 A ARP030101762 A AR P030101762A AR P030101762 A ARP030101762 A AR P030101762A AR 040090 A1 AR040090 A1 AR 040090A1
Authority
AR
Argentina
Prior art keywords
sildenafil citrate
hypertension
methyl
inhibitor
sildenafil
Prior art date
Application number
ARP030101762A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0211919A external-priority patent/GB0211919D0/en
Priority claimed from GB0229784A external-priority patent/GB0229784D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of AR040090A1 publication Critical patent/AR040090A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicación 1: El uso de una combinación de un inhibidor de fosfodiesterasa de tipo 5 (PDE5) específica de monofosfato de guanosina cíclico y un inhibidor de la enzima de conversión de la angiotensina (ACE) para la preparación de un medicamento caracterizado porque es para el tratamiento paliativo, curativo o profiláctico de la hipertensión, incluyendo hipertensión esencial, hipertensión pulmonar, hipertensión secundaria, hipertensión sistólica aislada, hipertensión asociada a diabetes, hipertensión asociada a aterosclerosis e hipertensión renovascular, insuficiencia cardíaca congestiva, angina, apoplejía, diabetes y alteración de la tolerancia a la glucosa. Reivindicación 4: El uso según cualquiera de las reivindicaciones precedentes, caracterizado porque el inhibidor de PDE5 se selecciona de 5-[2-etoxi-5-(4-metil-1-piperazinilsulfonil)fenil]-1-metil-3-n-propil-1,6-dihidro-7H-pirazolo[4,3-d]pirimidin-7-ona (sildenafilo) (6R,12aR)-2,3,6,7,12,12a-hexahidro-2-metil-6-(3,4-metilendioxifenil)-pirazino[2',1':6,1]pirido[3,4-b]indol-1,4-diona (tadalafilo); 2-[2-etoxi-5-(4-etilpiperazin-1-il-1-sulfonil)fenil]-5-metil-7-propil-3H-imidazo[5,1-f][1,2,4]triazin-4-ona (vardenafilo); 5-[2-etoxi-5-(4-etilpiperazin-1-ilsulfonil)piridin-3-il]-3-etil-2-[2-metoxietil]-2,6-dihidro-7H-pirazolo[4,3-d]pirimidin-7-ona; y 5-[5-acetil-2-butoxi-3-piridinil)-3-etil-2-(1-etil-3-azetidinil)-2,6-dihidro-7H-pirazolo[4,3-d]pirimidin-7-ona; y las sales farmacéuticamente aceptables de las mismas. Reivindicación 5: El uso según la reivindicación 4, caracterizado porque el inhibidor de PDE5 es 5-[2-etoxi-5-(4-metil-1-piperazinilsulfonil)fenil]-1-metil-3-n-propil-1,6-dihidro-7H-pirazolo[4,3-d]pirimidin-7-ona (sildenafilo) o una sal farmacéuticamente aceptable de la misma. Reivindicación 7: El uso según cualquiera de las reivindicaciones precedentes, caracterizado porque el inhibidor de ACE se selecciona de benazepril, captopril, cilazepril, enalapril, enalaprilat, fosinopril, lisinopril, moexepril, perindopril, quinapril, ramipril y trandolapril y las sales farmacéuticamente aceptables de los mismos. Reivindicación 8: El uso según la reivindicación 7, caracterizado porque la combinación del inhibidor de PDE5 y el inhibidor de ACE se selecciona de citrato de sildenafilo y clorhidrato de quinapril; citrato de sildenafilo y clorhidrato de benazepril; citrato de sildenafilo y captopril; citrato de sildenafilo y maleato de enalapril; citrato de sildenafilo y fosinopril; citrato de sildenafilo y lisinopril; citrato de sildenafilo y moexipril; citrato de sildenafilo y ramipril; citrato de sildenafilo y trandolapril.
ARP030101762A 2002-05-23 2003-05-21 Nueva combinacion AR040090A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0211919A GB0211919D0 (en) 2002-05-23 2002-05-23 Novel combination
GB0229784A GB0229784D0 (en) 2002-12-20 2002-12-20 Novel combination

Publications (1)

Publication Number Publication Date
AR040090A1 true AR040090A1 (es) 2005-03-16

Family

ID=29585817

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030101762A AR040090A1 (es) 2002-05-23 2003-05-21 Nueva combinacion

Country Status (18)

Country Link
EP (1) EP1506015A2 (es)
JP (1) JP2005529927A (es)
KR (1) KR20050004195A (es)
CN (1) CN1655820A (es)
AR (1) AR040090A1 (es)
AU (1) AU2003223071A1 (es)
BR (1) BR0311191A (es)
CA (1) CA2485984A1 (es)
IL (1) IL164975A0 (es)
MX (1) MXPA04010951A (es)
NO (1) NO20045517L (es)
PA (1) PA8574201A1 (es)
PE (1) PE20040514A1 (es)
PL (1) PL374198A1 (es)
RU (1) RU2004133973A (es)
TW (1) TW200407153A (es)
UY (1) UY27816A1 (es)
WO (1) WO2003099194A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7019010B2 (en) 2001-09-27 2006-03-28 Novertis Ag Combinations
GB0318094D0 (en) * 2003-08-01 2003-09-03 Pfizer Ltd Novel combination
DE102004011512B4 (de) 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmazeutische Zubereitung enthaltend Pimobendan
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
FR2902009B1 (fr) * 2006-06-13 2012-12-07 Bioprojet Soc Civ Utilisation d'un inhibiteur de vasopeptidase pour le traitement de l'hypertension arterielle pulmonaire
JP2010501577A (ja) 2006-08-24 2010-01-21 サーフェイス ロジックス，インコーポレイティド 薬物動態が改善された化合物
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
EP2825159B1 (en) 2012-03-15 2022-06-22 Boehringer Ingelheim Vetmedica GmbH Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
ES2860526T3 (es) 2013-07-19 2021-10-05 Boehringer Ingelheim Vetmedica Gmbh Derivados de ciclodextrina eterificada conservados que contienen una composición farmacéutica acuosa líquida
PL2925305T3 (pl) 2013-12-04 2017-07-31 Boehringer Ingelheim Vetmedica Gmbh Ulepszone kompozycje farmaceutyczne pimobendanu
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4316906A (en) * 1978-08-11 1982-02-23 E. R. Squibb & Sons, Inc. Mercaptoacyl derivatives of substituted prolines
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
GB9401090D0 (en) * 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
EP2295436A1 (de) * 1997-11-12 2011-03-16 Bayer Schering Pharma AG 2-Phenyl-substituierte Imidazotriazinone als Phosphodiesterase V Inhibitoren
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
CN1378547A (zh) * 1999-10-11 2002-11-06 辉瑞大药厂 用作磷酸二酯酶抑制剂的5－(2－取代的－5－杂环基磺酰基吡啶－3－基)－二氢吡唑并[4,3－d]嘧啶－7－酮类化合物

Also Published As

Publication number Publication date
NO20045517L (no) 2004-12-17
BR0311191A (pt) 2005-03-01
CA2485984A1 (en) 2003-12-04
CN1655820A (zh) 2005-08-17
PA8574201A1 (es) 2003-12-19
AU2003223071A1 (en) 2003-12-12
TW200407153A (en) 2004-05-16
JP2005529927A (ja) 2005-10-06
PL374198A1 (en) 2005-10-03
RU2004133973A (ru) 2005-09-10
WO2003099194A2 (en) 2003-12-04
KR20050004195A (ko) 2005-01-12
UY27816A1 (es) 2003-12-31
WO2003099194A3 (en) 2004-06-03
MXPA04010951A (es) 2005-06-08
EP1506015A2 (en) 2005-02-16
PE20040514A1 (es) 2004-08-24
IL164975A0 (en) 2005-12-18

Similar Documents

Publication Publication Date Title
AR040090A1 (es) Nueva combinacion
RU2008131792A (ru) Комбинация избирательного ингибитора обратного захвата норадреналина и ингибитора pdev
HRP20150987T1 (hr) UPORABA sGC STIMULATORA, sGC AKTIVATORA, SAMOSTALNO I U KOMBINACIJAMA S INHIBITORIMA PDE5 ZA LIJEÄŚENJE SISTEMSKE SKLEROZE (SSc)
US5366973A (en) Mercaptoacetylamido pyridazo [1,2]pyridazine, pyrazolo[1,2]pyridazine pyrazolo[1,2]pyridazine, pyridazol[1,2-a][1,2]diazepine and pyrazolol[1,2-a][1,2]diazepine
JP2013526598A5 (es)
US20040220186A1 (en) PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
CA2324324A1 (en) Treatment of pulmonary hypertension
AU2015349888A1 (en) Triazolo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
BG106383A (en) Imidazo[1,2-a]pyridine and pyrazolo[2,3-a]pyridine derivatives
NO20053955L (no) Pyrazolo [1,5-A] pyrimidinderivater
DE60204760D1 (de) Pyrazolo[4,3-d]pyrimidinon-verbindungen als cgmp pde-inhibitoren
JP2006528229A5 (es)
AR062501A1 (es) Composiciones terapeuticas
US20090312335A1 (en) Hiv Integrase Inhibitors
AR040337A1 (es) Uso de una combinacion de un inhibidor de fosfodiesterasa tipo 5 (pde5) especifica de monofosfato de guanosina ciclico (gmpc) y un antagonista del receptor de angiotensina ii para preparar un medicamento
JP2005529927A5 (es)
CA2072233A1 (en) Triazolopyrimidine derivatives which are angiotensin ii receptor antagonists; processes for preparing them and pharmaceutical compositions containing them
US5366994A (en) Use of a combination of angiotensin-converting enzyme inhibitor and calcium antagonist for the treatment of proteinuria
US20080171746A1 (en) Method for Preventing Cardiovascular Diseases
JP2005531627A5 (es)
DE69930416D1 (de) Cgmp pde5 inhibitoren zur inhalationsbehandlung von sexueller dysfunktion
US20040077624A1 (en) Novel combination
AU3889301A (en) Blood pressure stabilization during hemodialysis
PT833837E (pt) Processo para a preparacao de derivados de acido azabiciclo-naftiridinocarboxilico compreendendo um dipeptideo
CN116102617A (zh) 一种具有ace抑制活性的活性肽及其筛选方法和应用

Legal Events

Date Code Title Description
FB Suspension of granting procedure